Avadel gets tentative FDA nod for rival to Jazz narcolepsy drug

[cafead]

via Avadel Pharmaceuticals has taken a step toward challenging Jazz Pharmaceuticals for the narcolepsy market. The FDA granted tentative approval to the company’s extended-release rival to Xyrem, leaving a patent as the last barrier between it and the market.

article source